Pieris Pharmaceuticals In... (PIRS)
13.60
-2.51 (-15.58%)
At close: Dec 13, 2024, 9:00 PM
Pieris Pharmaceuticals Cash Flow Statement
| Year | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 |
| Net Income | -24.54M | -33.28M | -45.74M | -37.23M | -25.47M | -26.75M | -17.65M | -22.8M | -14.06M | -9.85M | 66.2K | -2.32M |
| Depreciation & Amortization | 1.78M | 2.78M | 2.37M | 2.13M | 1.04M | 570K | 369K | 361.38K | 307.91K | 366.98K | 384.68K | 378.32K |
| Stock-Based Compensation | 3.35M | 4.4M | 5.21M | 5.09M | 5.37M | 4.94M | 3.05M | 1.91M | 1.16M | 571.38K | n/a | n/a |
| Other Working Capital | -11.9M | -26.54M | 19.55M | -14.5M | -28.52M | 8.62M | 74.38M | 3.75M | -699.85K | 70.03K | 114.26K | n/a |
| Other Non-Cash Items | -22.5M | -467K | -30K | 330K | -69K | -1.55M | 293K | 1.91M | 671.4K | 2.59M | 414.27K | -7.15M |
| Deferred Income Tax | -4.52M | n/a | n/a | 164K | -1.22M | -164K | 156K | -1.86M | n/a | 664.06K | n/a | n/a |
| Change in Working Capital | -7.38M | -33.37M | 30.52M | -16.38M | -32.12M | 21.89M | 63.54M | 6.1M | -790.78K | 592.81K | -3.94M | -123.24K |
| Operating Cash Flow | -53.82M | -59.93M | -7.66M | -45.9M | -52.47M | -1.07M | 49.75M | -14.39M | -12.71M | -5.07M | -3.08M | -9.09M |
| Capital Expenditures | -171K | -1.04M | -949K | -2.73M | -2.46M | -1.7M | -1.95M | -580.64K | -620.75K | -267.41K | -49.47K | -132.73K |
| Acquisitions | -12.17M | 20.2M | n/a | -41.94M | -12.3M | n/a | n/a | 20.97K | n/a | n/a | n/a | n/a |
| Purchase of Investments | -22.84M | -48.4M | n/a | -41.5M | -59.32M | -117.58M | -43.92M | n/a | n/a | n/a | n/a | n/a |
| Sales Maturities Of Investments | 35.01M | 28.2M | n/a | 83.44M | 71.62M | 110.41M | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Investing Acitivies | 12.17M | -20.2M | n/a | 41.94M | 12.3M | -7.18M | -43.92M | 20.97K | n/a | n/a | n/a | 90.00 |
| Investing Cash Flow | 12M | -21.24M | -949K | 39.21M | 9.84M | -8.88M | -45.88M | -559.67K | -620.75K | -267.41K | -49.47K | -132.64K |
| Debt Repayment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | -1.16M | 1.03M | 327.21K | n/a |
| Common Stock Repurchased | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Dividend Paid | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Other Financial Acitivies | 19.8M | 292K | 2.03M | 491K | 1.17M | 1.3M | 4.09M | 21.00 | 10K | 7.34M | n/a | 2.32M |
| Financial Cash Flow | 19.8M | 7.21M | 59.13M | 10.12M | 32.17M | 48.51M | 4.09M | 15.22M | 24.62M | 20.33M | 327.21K | 2.32M |
| Net Cash Flow | -21.24M | -79.13M | 47.33M | 8.18M | -12.61M | 36.99M | 8.52M | 6.4K | 10.87M | 14.78M | -2.64M | -6.89M |
| Free Cash Flow | -53.99M | -60.97M | -8.61M | -48.62M | -54.93M | -2.76M | 47.8M | -14.97M | -13.33M | -5.33M | -3.13M | -9.22M |